Advances in molecular mechanisms underlying the promotion of cancer development and progression by EphA2
10.19405/j.cnki.issn1000–1492.2026.06.022
- VernacularTitle:EphA2促进肿瘤发生和进展分子机制的研究进展
- Author:
Hui YU
1
;
Chen HAN
2
;
Shili WANG
1
;
Haihong YANG
1
;
Peiyuan LU
1
Author Information
1. School of Medicine， Shandong Xiehe University， Jinan 250109
2. School of Clinical and Basic Medical Sciences， Shandong First Medical University， Jinan 250117
- Publication Type:Review
- Keywords:
EphA2;
cancer development;
cancer progression;
tyrosine phosphorylation;
receptor tyrosine kinases;
signaling pathways
- From:
Acta Universitatis Medicinalis Anhui
2026;61(6):1151-1156
- CountryChina
- Language:Chinese
-
Abstract:
Erythropoietin-producing hepatoma receptor A2 （EphA2） is a member of the erythropoietin-producing hepatoma （Eph） subfamily of receptor tyrosine kinases. As a critical regulator of cancer development and progression， EphA2 can promote tumor initiation， growth， invasion， metastasis， stemness， and angiogenesis by activating or enhancing the oncogenic signaling pathways. High expression of EphA2 in tumor tissues is closely associated with poor prognosis， thus it is a very promising potential target for cancer treatment. This article reviews the molecular mechanisms by which EphA2 promotes cancer development and progression， aiming to provide clues and theoretical basis for EphA2-targeted cancer treatment.
